PFOS and Its Commercial Alternative, 6:2 Cl-PFESA, Induce Multidrug Resistance in Pancreatic Cancer
The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Abstract
Per- and polyfluoroalkyl substances (PFAS), specifically perfluorooctanesulfonate (PFOS) and its alternative, 2-[(6-chloro-1,1,2,2,3,3,4,4,5,5,6,6-dodecafluorohexyl)oxy]-1,1,2,2-tetrafluoroethanesulfonic acid (6:2 Cl-PFESA), are associated with environmental health concerns and potential cancer progression. However, their impact on multidrug resistance (MDR) in pancreatic cancer (PC) chemotherapy remains unclear. Here, we employed drug-sensitivity assays, including IC 50 calculations, in vitro and in vivo models with various chemotherapeutics, and paclitaxel (PTX) as a representative agent, combined with transcriptomic/proteomic sequencing and clinical prognostic analysis, to identify MDR-related genes and validate their relevance, with the objective of establishing the correlation between PFOS/6:2 Cl-PFESA exposure and MDR in PC at molecular, cellular, and animal model levels. Our findings demonstrate that PFOS/6:2 Cl-PFESA exposure increases the drug IC 50 in three different PC cell lines for various chemotherapeutic agents. Compared with PFOS, 6:2 Cl-PFESA demonstrated a more pro-MDR effect on PC cells in vitro . In vivo experiments further revealed that PFOS/6:2 Cl-PFESA exposures significantly reduced the efficacy of PTX in PC, with inhibition rates dropping from 78.3% to 23.8%/6.1%, respectively ( p < 0.05). This effect was driven by the aberrant activation of the PI3K-ABCB1 pathway, with 6:2 Cl-PFESA demonstrating a stronger capacity to promote this signal pathway's ex…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“HFPO oligomers and 6:2 Cl-PFESA demonstrated significantly higher accumulation factors than their predecessors, PFOA in fluorochemical production and PFOS in chrome plating, respectively42,43”
From Identification of a PFAS hyperaccumulator and elucidation of its translocation mechanism for sustainable phytoremediation (2025) · cites this paper as [43]
Citations
Cites
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Vincent, A., Herman, J., Schulick, R., Hruban, R. H., & Goggins, M. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62307-0 · Cited by 2,586
Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors
Klein, A. P. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00457-x · Cited by 1,258
Acquired Resistance to KRAS G12C Inhibition in Cancer
Awad, M. M., Liu, S., Rybkin, I. I., Arbour, K. C., Dilly, J., Zhu, V. W., Johnson, M. L., Heist, R. S., Patil, T., Riely, G. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105281 · Cited by 1,247
Therapeutic developments in pancreatic cancer: current and future perspectives
Neoptolemos, J. P., Kleeff, J., Michl, P., Costello, E., Greenhalf, W., & Palmer, D. H. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0005-x · Cited by 1,170
mTOR signalling and cellular metabolism are mutual determinants in cancer
Mossmann, D., Park, S., & Hall, M. N. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0074-8 · Cited by 1,088
Targeting tumor-associated macrophages to synergize tumor immunotherapy
Xiang, X., Wang, J., Lu, D., & Xu, X. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00484-9 · Cited by 966
Acquired Resistance to Immune Checkpoint Inhibitors
Schoenfeld, A. J., & Hellmann, M. D. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.017 · Cited by 955
Optimizing the outcomes of pancreatic cancer surgery
Strobel, O., Neoptolemos, J., Jäger, D., & Büchler, M. W. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0112-1 · Cited by 943
Challenges and Opportunities for Pancreatic Cancer Immunotherapy
Bear, A. S., Vonderheide, R. H., & O'Hara, M. H. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.004 · Cited by 674
Erin, N., Grahovac, J., Brozovic, A., & Efferth, T. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100715 · Cited by 527
Effective drug combinations in breast, colon and pancreatic cancer cells
Jaaks, P., Coker, E. A., Vis, D. J., Edwards, O., Carpenter, E. F., Leto, S. M., Dwane, L., Sassi, F., Lightfoot, H., Barthorpe, S., et al. (2022) · Nature · doi:10.1038/s41586-022-04437-2 · Cited by 469
Perfluoroalkyl and polyfluoroalkyl substances (PFAS) and their effects on the ovary
Ding, N., Harlow, S. D., Randolph Jr, J. F., Loch-Caruso, R., & Park, S. K. (2020) · Human Reproduction Update · doi:10.1093/humupd/dmaa018 · Cited by 400
Duan, C., Yu, M., Xu, J., Li, B.-Y., Zhao, Y., & Kankala, R. K. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114643 · Cited by 335
Microenvironmental Determinants of Pancreatic Cancer
Hessmann, E., Buchholz, S. M., Demir, I. E., Singh, S. K., Gress, T. M., Ellenrieder, V., & Neesse, A. (2020) · Physiological Reviews · doi:10.1152/physrev.00042.2019 · Cited by 331
Roth, K., Yang, Z., Agarwal, M., Liu, W., Peng, Z., Long, Z., Birbeck, J., Westrick, J., Liu, W., & Petriello, M. C. (2021) · Environment International · doi:10.1016/j.envint.2021.106843 · Cited by 307
Sen, P., Qadri, S., Luukkonen, P. K., Ragnarsdottir, O., McGlinchey, A., Jäntti, S., Juuti, A., Arola, J., Schlezinger, J. J., Webster, T. F., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.09.039 · Cited by 290
Therapeutic strategies to overcome taxane resistance in cancer
Das, T., Anand, U., Pandey, S. K., Ashby, C. R., Assaraf, Y. G., Chen, Z.-S., & Dey, A. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100754 · Cited by 253
Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy
Koikawa, K., Kibe, S., Suizu, F., Sekino, N., Kim, N., Manz, T. D., Pinch, B. J., Akshinthala, D., Verma, A., Gaglia, G., et al. (2021) · Cell · doi:10.1016/j.cell.2021.07.020 · Cited by 233
Mastrantonio, M., Bai, E., Uccelli, R., Cordiano, V., Screpanti, A., & Crosignani, P. (2018) · European Journal of Public Health · doi:10.1093/eurpub/ckx066 · Cited by 228
Kunzmann, V., Siveke, J. T., Algül, H., Goekkurt, E., Siegler, G., Martens, U., Waldschmidt, D., Pelzer, U., Fuchs, M., Kullmann, F., et al. (2021) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(20)30330-7 · Cited by 209
Zhou, Z., Shi, Y., Vestergren, R., Wang, T., Liang, Y., & Cai, Y. (2014) · Environmental Science & Technology · doi:10.1021/es4057467 · Cited by 207
Memon, D., Schoenfeld, A. J., Ye, D., Fromm, G., Rizvi, H., Zhang, X., Keddar, M. R., Mathew, D., Yoo, K. J., Qiu, J., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2023.12.013 · Cited by 207
Environmental chemicals, breast cancer progression and drug resistance
Koual, M., Tomkiewicz, C., Cano-Sancho, G., Antignac, J.-P., Bats, A.-S., & Coumoul, X. (2020) · Environmental Health · doi:10.1186/s12940-020-00670-2 · Cited by 204
(2021) · doi:10.3322/caac.21697 · Cited by 201
Schuth, S., Blanc, S. L., Krieger, T. G., Jabs, J., Schenk, M., Giese, N. A., Büchler, M. W., Eils, R., Conrad, C., & Strobel, O. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02519-7 · Cited by 192
Hu, B., Zou, T., Qin, W., Shen, X., Su, Y., Li, J., Chen, Y., Zhang, Z., Sun, H., Zheng, Y., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-4140 · Cited by 184
Self-citationChang, E. T., Adami, H.-O., Boffetta, P., Cole, P., Starr, T. B., & Mandel, J. S. (2014) · Critical Reviews in Toxicology · doi:10.3109/10408444.2014.905767 · Cited by 180
Dong, J., Yuan, L., Hu, C., Cheng, X., & Qin, J.-J. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108488 · Cited by 178
Seufferlein, T., Uhl, W., Kornmann, M., Algül, H., Friess, H., König, A., Ghadimi, M., Gallmeier, E., Bartsch, D. K., Lutz, M. P., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.09.161 · Cited by 168
LaPensee, E. W., Tuttle, T. R., Fox, S. R., & Ben‐Jonathan, N. (2008) · Environmental Health Perspectives · doi:10.1289/ehp.11788 · Cited by 163
Pemetrexed (ALIMTA), A Novel Multitargeted Antineoplastic Agent
Adjei, A. A. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-040010 · Cited by 162
Evaluation of P-Glycoprotein Inhibitory Potential Using a Rhodamine 123 Accumulation Assay
Jouan, E., Vée, M. L., Mayati, A., Denizot, C., Parmentier, Y., & Fardel, O. (2016) · Pharmaceutics · doi:10.3390/pharmaceutics8020012 · Cited by 156
Zhong, T., Zhang, W., Guo, H., Pan, X., Chen, X., He, Q., Yang, B., & Ding, L. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.11.001 · Cited by 145
Self-citationBrusatol, an NRF2 inhibitor for future cancer therapeutic
Cai, S. J., Liu, Y., Han, S., & Yang, C. (2019) · Cell & Bioscience · doi:10.1186/s13578-019-0309-8 · Cited by 142
Song, Y., Bugada, L. F., Li, R., Hu, H., Zhang, L., Li, C., Yuan, H., Rajanayake, K. K., Truchan, N. A., Wen, F., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abl3649 · Cited by 139
DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells
Saiki, Y., Yoshino, Y., Fujimura, H., Manabe, T., Kudo, Y., Shimada, M., Mano, N., Nakano, T., Lee, Y., Shimizu, S., et al. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.03.122 · Cited by 114
Organoids for Functional Precision Medicine in Advanced Pancreatic Cancer
Boilève, A., Cartry, J., Goudarzi, N., Bedja, S., Mathieu, J. R. R., Bani, M. A., Nicolle, R., Mouawia, A., Bouyakoub, R., Nicotra, C., et al. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.05.032 · Cited by 112
Yu, B., Wang, Y., Bing, T., Tang, Y., Huang, J., Xiao, H., Liu, C., & Yu, Y. (2023) · Advanced Materials · doi:10.1002/adma.202310456 · Cited by 112
Steitz, J., Br�ck, J., Steinbrink, K., Enk, A., Knop, J. X. F. R., & Tüting, T. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000401)86:1<15::aid-ijc3>3.0.co;2-b · Cited by 106
Emerging nanomedicines of paclitaxel for cancer treatment
Chen, Q., Xu, S., Liu, S., Wang, Y., & Liu, G. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.010 · Cited by 104
Zhang, Y., Liu, X., Wang, Y., Lai, S., Wang, Z., Yang, Y., Liu, W., Wang, H., & Tang, B. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01647-0 · Cited by 104
Al-Sawaf, O., Zhang, C., Jin, H. Y., Robrecht, S., Choi, Y., Balasubramanian, S., Kotak, A., Chang, Y. M., Fink, A. M., Tausch, E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37648-w · Cited by 94
Self-citationDing, N., Harlow, S. D., Batterman, S., Mukherjee, B., & Park, S. K. (2020) · Environment International · doi:10.1016/j.envint.2019.105381 · Cited by 79
Liu, Y., Azizian, N. G., Sullivan, D. K., & Li, Y. (2022) · Nature Communications · doi:10.1038/s41467-022-34890-6 · Cited by 79
Zhang, L., Li, Y., Hu, C., Chen, Y., Chen, Z., Chen, Z., Zhang, J., & Fang, S. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01524-w · Cited by 76
Self-citationUnravelling the enigma of siRNA and aptamer mediated therapies against pancreatic cancer
Liu, Z., Parveen, N., Rehman, U., Aziz, A., Sheikh, A., Abourehab, M. A. S., Guo, W., Huang, J., Wang, Z., & Kesharwani, P. (2023) · Molecular Cancer · doi:10.1186/s12943-022-01696-5 · Cited by 75
Wang, W., Wang, J., Liu, S., Ren, Y., Wang, J., Liu, S., Cui, W., Jia, L., Tang, X., Yang, J., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01579-9 · Cited by 74
Cao, L., Guo, Y., Chen, Y., Hong, J., Wu, J., & Hangbiao, J. (2022) · Chemosphere · doi:10.1016/j.chemosphere.2022.134083 · Cited by 71
Self-citationAssociation of multi‐drug resistance gene polymorphisms with pancreatic cancer outcome
Tanaka, M., Okazaki, T., Suzuki, H., Abbruzzese, J. L., & Li, D. (2010) · Cancer · doi:10.1002/cncr.25510 · Cited by 65
Inhibition of Autophagy by Deguelin Sensitizes Pancreatic Cancer Cells to Doxorubicin
Xu, X., Zhao, Y., Zhang, M., He, R., Shi, X., Guo, X., Shi, C.-J., Peng, F., Wang, M., Shen, M., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020370 · Cited by 60
LaPensee, E. W., LaPensee, C. R., Fox, S. R., Schwemberger, S. J., Afton, S. E., & Ben‐Jonathan, N. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.09.005 · Cited by 58
Jiang, W., Chen, L., Guo, X., Chen, C., Luo, Y., Wang, J., Wang, J., Liu, Y., Cao, Y., Li, P., et al. (2022) · Theranostics · doi:10.7150/thno.71693 · Cited by 54
Bie, N., Yong, T., Wei, Z., Liang, Q., Zhang, X., Li, S., Li, X., Li, J., Gan, L., & Yang, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01658-3 · Cited by 53
Bergonzini, C., Gregori, A., Hagens, T. M. S., van der Noord, V. E., van de Water, B., Zweemer, A. J. M., Coban, B., Capula, M., Mantini, G., Botto, A., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02879-8 · Cited by 49
Hong, J., Du, K., Jin, H., Chen, Y., Jiang, Y., Zhang, W., Chen, D., Zheng, S., & Cao, L. (2024) · Environment International · doi:10.1016/j.envint.2024.108582 · Cited by 47
Self-citationTunggal, J. K., Melo, T., Ballinger, J. R., & Tannock, I. F. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000401)86:1<101::aid-ijc16>3.0.co;2-i · Cited by 47
Zhao, L., Pan, Y., Yi, G., Wang, H., Jin, H., Tie, J., Xia, L., Zhang, Y., He, L., Yao, L., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.028068 · Cited by 45
Self-citationTargeted nanodelivery of siRNA against KRAS G12D inhibits pancreatic cancer
Huang, R., Du, H., Cheng, L., Zhang, P., Meng, F., & Zhong, Z. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.07.008 · Cited by 40
Zhou, J., Zhang, L., Zheng, H., Ge, W., Huang, Y., Yan, Y., Zhou, X., Zhu, W., Kong, Y., Ding, Y., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2764 · Cited by 40
P‐Glycoprotein Inhibition Exacerbates Paclitaxel Neurotoxicity in Neurons and Patients With Cancer
Stage, T. B., Mortensen, C., Khalaf, S., Steffensen, V., Hammer, H., Xiong, C., Nielsen, F., Poetz, O., Svenningsen, Å. F., Rodríguez‐Antona, C., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1847 · Cited by 40
Qi, G., Shi, G., Wang, S., Hu, H., Zhang, Z., Yin, Q., Li, Z., & Hao, L. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s436253 · Cited by 40
Li, C., Jiang, L., Zhang, D., Qi, Y., Wang, X., Jin, Y., Liu, X., Lin, Y., Luo, J., Xu, L., et al. (2023) · Environment International · doi:10.1016/j.envint.2023.107846 · Cited by 38
Rickard, B. P., Tan, X. M., Fenton, S. E., & Rizvi, I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095176 · Cited by 34
Qu, Y. Q., Song, L., Xu, S., Yu, M. S. Y., Kadioglu, O., Michelangeli, F., Law, B. Y. K., Efferth, T., Lam, C. W.-K., & Wong, V. K. W. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106769 · Cited by 29
Hong, J., Wang, X., Jin, H., Chen, Y., Jiang, Y., Du, K., Chen, D., Zheng, S., & Cao, L. (2023) · Environmental Pollution · doi:10.1016/j.envpol.2023.122910 · Cited by 23
Self-citationTaha, M. S., Nocera, A. L., Workman, A. D., Amiji, M. M., & Bleier, B. S. (2021) · Rhinology Journal · doi:10.4193/rhin20.551 · Cited by 21
Rickard, B. P., Overchuk, M., Tulino, J., Tan, X. M., Ligler, F. S., Bae-Jump, V. L., Fenton, S. E., & Rizvi, I. (2023) · Environmental Health · doi:10.1186/s12940-023-01034-2 · Cited by 21
Lin, R., Zhang, L., Ye, B., Wang, Y., Li, Y.-D., Jason, H., Liu, W., Hu, P., Chen, J., Chen, Z., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216181 · Cited by 20
Barnett, C., Joubert, F., Iliopoulou, A., Álvarez, R. S., & Pasparakis, G. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c01012 · Cited by 17
Ushio, H., Ishibuchi, S., Oshita, K., Seki, N., Kataoka, H., Sugahara, K., Adachi, K., & Chiba, K. (2013) · Pharmaceuticals · doi:10.3390/ph7010001 · Cited by 16
Yang, Y., Teng, Q., Wu, Z., Wang, J., Lei, Z., Lusvarghi, S., Ambudkar, S. V., Ji, N., & Chen, Z. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01512-0 · Cited by 16
Jang, G., Oh, J., Jun, E., Lee, J. L., Kwon, J. Y., Kim, J., Lee, S., Kim, S. C., Cho, S., & Lee, C. (2022) · npj Genomic Medicine · doi:10.1038/s41525-022-00333-w · Cited by 15
Mortality and cancer incidence in perfluorooctanesulfonyl fluoride production workers
Alexander, B. H., Ryan, A. D., Church, T. R., Kim, H. S., Olsen, G. W., & Logan, P. W. (2024) · American Journal of Industrial Medicine · doi:10.1002/ajim.23568 · Cited by 15
Activity of vinorelbine in gastrointestinal cancers
Conroy, T. (2002) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(01)00180-9 · Cited by 12
Hong, J., Du, K., Zhang, W., Chen, J., Jin, H., Chen, Y., Jiang, Y., Yu, H., Weng, X., Zheng, S., et al. (2024) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2024.134790 · Cited by 12
Self-citationWeng, W.-W., Hong, J., Owusu-Ansah, K. G., Chen, B., Zheng, S., & Jiang, D. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e12064 · Cited by 8
Self-citationZeng, M., Sun, S. B., Feng, H., Tan, Z., Zhao, J., Wu, Y., Yuan, W., Li, Z., Qiu, J., Niu, M., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116943 · Cited by 8
Research works printed but not linked: 1
- Hong J., 2020, Am. J. Transl. Res., 12, 551
Cited by
Guo, X., Zhang, X., Chen, J., Shan, W., Wang, R., Wang, K., Chen, Z., Wang, L., & Zhang, Y. (2025) · Nature Communications · doi:10.1038/s41467-025-65191-3 · Cited by 18
“Forexample,HFPOoligomersand 6:2 Cl-PFESA demonstrated signi fi cantly higher accumulation factors than their predecessors, PFOA in fl uorochemicalproductionand PFOS in chrome plating, respectively 42,43 (Supplementary Fig.”
Briassoulis, G., Ilia, S., & Briassouli, E. (2025) · Life · doi:10.3390/life15071057 · Cited by 15
“This systemic disruption has potential implications for multi-drug resistance (MDR): notably, 6:2 Cl-PFESA, a PFOS substitute, has been shown to influence MDR mechanisms, underlining the need for rigorous evaluations of its carcinogenic potential [114].”
Xu, D., Xiang, J., Qin, R., Chen, Z., Wang, X., Xu, P., Pan, Y., Zhang, X., Wang, Y., Cheng, P., et al. (2025) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2025.139882 · Cited by 5
Self-citationLiu, J., Pang, X., Li, X., Huang, N., Xu, J., Wu, Q., Yao, R., Liu, B., Lu, H., & Lian, J. (2025) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2025.140583 · Cited by 3
Jiang, J., Meng, H., Shu, Z., Zhao, N., Lin, X., Li, J., Qin, M., Wu, S., & Qiu, L. (2026) · Environmental Science & Technology · doi:10.1021/acs.est.5c11476 · Cited by 2
Metadata
- Authors
- Hong, J., Du, K., Zhang, W., Jiang, Y., Yu, H., Pan, T., Wu, T., Zhao, L., Du, W., Zheng, S.-S., Jin, H., Chen, Y., & Cao, L.
- Affiliations
- First Affiliated Hospital Zhejiang University (CN)
- Zhejiang University (CN)
- NHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou 310003, PR China
- Chinese Research Academy of Environmental Sciences (CN)
- Kunming University of Science and Technology (CN)
- Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, PR China
- Zhejiang University of Technology (CN)
- Corresponding author
- Jin, Hangbiao
- Chen, Yuanchen
- Cao, Linping
- ORCID
- Venue
- Environmental Science & Technology
- Publisher
- American Chemical Society (ACS)
- Published
- 2024-12-07
- Volume
- 58
- Issue
- 50
- Pages
- 22027-22038
- ISSN
- 0013-936X (ISSN-L)
- 1520-5851
- OpenAlex
- W4405130441
- Cited by
- 16
- References
- 77
- Citations by year
- 2026: 12 · 2025: 4
- FWCI
- 2.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Environmental Science & Technology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Fundamental Research Funds for the Central Universities (226-2024-00117)
- National Natural Science Foundation of China (21806139, 42177390)
- Innovative Research Groups of National Natural Science Foundation of China (81721091)
- Topics
- Physical Sciences › Environmental Science › Environmental Chemistry › Per- and polyfluoroalkyl substances research
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Keywords
- PFOS, per- and polyfluoroalkyl substances, multidrug resistance, pancreatic cancer, paclitaxel, P-glycoprotein, chemotherapeutic drug resistance, PFAS alternatives, cancer risk assessment
- MeSH terms
- Animals, Fluorocarbons, Humans, Pancreatic Neoplasms, Alkanesulfonic Acids, Drug Resistance, Multiple, Drug Resistance, Neoplasm, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.